DAX24.092 +0,7%ESt505.376 +0,4%Top 10 Crypto14,12 -0,3%Dow42.520 +0,5%Nas19.399 +0,8%Bitcoin92.779 +0,2%Euro1,1369 -0,1%Öl65,47 -0,2%Gold3.353 ±0,0%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 RENK RENK73 NVIDIA 918422 BioNTech (ADRs) A2PSR2 HENSOLDT HAG000 Lufthansa 823212 BYD A0M4W9 Tesla A1CX3T Siemens Energy ENER6Y Gerresheimer A0LD6E BASF BASF11 Mercedes-Benz Group (ex Daimler) 710000 Bayer BAY001 Deutsche Telekom 555750 Deutsche Bank 514000
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Rekord wieder in Reichweite? DAX dürfte Aufwärtstrend fortsetzen -- Gewinne an den Börsen in Asien -- CrowdStrike mit überraschendem Verlust - Neues Gesetz: Elon Musk legt sich mit Donald Trump an
Top News
Wells Fargo-Aktie höher: Wells Fargo darf wieder wachsen - Fed hebt Beschränkungen auf Wells Fargo-Aktie höher: Wells Fargo darf wieder wachsen - Fed hebt Beschränkungen auf
US-Beschäftigungsdaten im Fokus: DAX im Mittwochshandel höher erwartet - Rekordhoch wieder im Blick US-Beschäftigungsdaten im Fokus: DAX im Mittwochshandel höher erwartet - Rekordhoch wieder im Blick
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Precigen Aktie

Handeln
Precigen Aktien-Sparplan
1,16 EUR +0,02 EUR +2,12 %
FSE
1,36 USD +0,04 USD +2,65 %
BTT
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.344,89 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA2PZG1

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS74017N1054

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolPGEN

Precigen Aktien News

DatumMeistgelesen
PR NewswirePrecigen Reports First Quarter 2025 Financial Results and Business Updates
PR NewswirePrecigen and Recurrent Respiratory Papillomatosis Foundation to Host the 2025 International RRP Awareness Day on June 11th
PR NewswirePrecigen Reports Full Year 2024 Financial Results and Business Updates
Wer­bungPrecigen-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
PR NewswirePrecigen to Announce Full Year 2024 Financial Results and Provide Business Updates on March 19th
PR NewswireFDA Grants Priority Review to Precigen's BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025
PR NewswirePrecigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference
PR NewswirePrecigen to Present at the 43rd Annual J.P. Morgan Healthcare Conference
PR NewswirePrecigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis
PR NewswirePrecigen Reports Third Quarter 2024 Financial Results and Business Updates
PR NewswirePrecigen to Participate in the Stifel 2024 Healthcare Conference
PR NewswirePrecigen to Participate in the 2024 Cantor Global Healthcare Conference
PR NewswirePrecigen Reports Second Quarter and First Half 2024 Financial Results and Business Updates
PR NewswirePrecigen to Announce Second Quarter and First Half 2024 Financial Results on August 14th
PR NewswirePrecigen Strategically Prioritizes Portfolio to Focus on First Potential Gene Therapy Launch
PR NewswirePrecigen Appoints Phil Tennant as Chief Commercial Officer to Spearhead First Potential Gene Therapy Launch
PR NewswirePrecigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response
PR NewswirePrecigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent Respiratory Papillomatosis Presented at the 2024 ASCO Annual Meeting
PR NewswirePrecigen Reports First Quarter 2024 Financial Results and Business Updates
PR NewswirePrecigen to Announce First Quarter 2024 Financial Results on May 14th and Host a Conference Call on June 3rd following the Late-breaking Oral Presentation for PRGN-2012 at the 2024 ASCO Annual Meeting
PR NewswirePrecigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024...
PR NewswireActym Therapeutics Appoints Thomas Smart as CEO
PR NewswirePrecigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th
PR NewswirePrecigen Reports Full Year 2023 Financial Results and Business Updates
PR NewswirePrecigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis
PR NewswirePrecigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th
PR NewswirePrecigen to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
PR NewswirePrecigen Receives Orphan Drug Designation for PRGN-2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission
PR NewswirePrecigen Highlights Pipeline Updates to be Presented at the 42nd Annual J.P. Morgan Healthcare Conference
PR NewswirePrecigen to Present at the 42nd Annual J.P. Morgan Healthcare Conference
PR NewswirePrecigen to Participate in the JMP Securities Hematology and Oncology Summit
PR NewswirePrecigen Reports Third Quarter 2023 Financial Results and Progress of Clinical Programs
PR NewswirePrecigen to Participate in the Stifel 2023 Healthcare Conference
PR NewswirePrecigen to Participate in Upcoming Leading Investor and Industry Conferences
PR NewswirePrecigen Reports Second Quarter and First Half 2023 Financial Results and Provides Update on Portfolio Prioritization and Capital Allocation Strategies to Extend Projected Cash Runway into 2025
PR NewswirePrecigen Announces FDA Confirmation that the Ongoing Phase 1/2 Study of PRGN-2012 AdenoVerse Immunotherapy Will Serve as the Pivotal Study to Support Accelerated Approval
PR NewswirePrecigen to Announce Second Quarter and First Half 2023 Financial Results on August 9th
PR NewswirePrecigen Receives Breakthrough Therapy Designation for PRGN-2012 AdenoVerse™ Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis
PR NewswirePrecigen Announces Positive Phase 1 Data for PRGN-3005 Autologous UltraCAR-T® Cells Manufactured Overnight for Infusion Next Day to Advanced Stage Platinum Resistant Ovarian Cancer Patients
PR NewswirePrecigen Announces Positive Phase 1 Data for Off-the-Shelf PRGN-2009 AdenoVerse™ Immunotherapy Alone and in Combination with an Investigational Checkpoint Inhibitor in Patients with Recurrent/Meta...
PR NewswirePrecigen Receives FDA Clearance of IND to Initiate Phase 2 Study of PRGN-2009 Off-the-Shelf AdenoVerse Immunotherapy in Combination with Pembrolizumab to Treat Patients with Recurrent or Metastati...
Wer­bung

Precigen News

Precigen News: auf dieser Seite finden Sie alle Precigen News und Nachrichten zur Precigen Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Precigen News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Precigen News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.